No Data
No Data
Climb Bio's Strategic Advancements and Promising Pipeline Drive Buy Rating
Climb Bio to Present at the 24th Annual Needham Virtual Healthcare Conference
Climb Bio Advances Clinical Trials and Expands Pipeline
Climb Bio Fueled Up With Cash, Poised for More Milestones in '25 – Quarterly Update Report
Express News | Climb Bio Inc: Files for Offering of Common Stock up to $22.4 Mln - SEC Filing
Eliem Therapeutics GAAP EPS of -$0.13 Beats by $0.02